ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 114 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $351,000 | +111.4% | 183,867 | +230.0% | 0.00% | +200.0% |
Q1 2022 | $166,000 | -23.5% | 55,713 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $217,000 | +239.1% | 55,713 | +82.1% | 0.00% | 0.0% |
Q2 2019 | $64,000 | -17.9% | 30,593 | +40.4% | 0.00% | 0.0% |
Q1 2019 | $78,000 | – | 21,796 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 3,705,128 | $10,300,000 | 4.44% |
RTW INVESTMENTS, LP | 5,666,754 | $15,754,000 | 0.59% |
COWEN AND COMPANY, LLC | 926,200 | $2,575,000 | 0.22% |
Hudson Bay Capital Management LP | 850,000 | $2,363,000 | 0.05% |
LADENBURG THALMANN FINANCIAL SERVICES INC. | 1,774,915 | $4,934,000 | 0.03% |
Point72 Asset Management, L.P. | 1,897,284 | $5,274,000 | 0.03% |
683 Capital Management, LLC | 77,368 | $215,000 | 0.02% |
Secure Asset Management, LLC | 10,000 | $28,000 | 0.02% |
Qube Research & Technologies Ltd | 166,138 | $462,000 | 0.01% |
Verition Fund Management LLC | 174,455 | $485,000 | 0.01% |